img

Global Nucleic Acid-based Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Latest Trends

Publisher : MRA | Format : PDF

Global Nucleic Acid-based Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Due to the COVID-19 pandemic, the global Nucleic Acid-based Drugs market size was US$ million in 2023 and is forecast to a readjusted size of US$ million by 2033 with a CAGR of % during the forecast period 2023-2033. Fully considering the economic change by this health crisis, ASO accounting for % of the Nucleic Acid-based Drugs global market in 2023, is projected to value US$ million by 2033, growing at a revised % CAGR from 2023 to 2033. While Genetic Disease segment is altered to an % CAGR throughout this forecast period.
The global key companies of Nucleic Acid-based Drugs include Ionis Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku, BioNTech, Moderna Therapeutics, CureVac, Alnylam Pharmaceuticals, Regulus Therapeutics and Miragen Therapeutics, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
The United States Nucleic Acid-based Drugs market size was US$ million in 2023, while China size was US$ million. The proportion of the United States was % in 2023, while China percentage was %, and it is predicted that China share will reach % in 2033, trailing a CAGR of % through the analysis period. As for the Europe Nucleic Acid-based Drugs landscape, Germany is projected to reach US$ million by 2033. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Nucleic Acid-based Drugs market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Nucleic Acid-based Drugs market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Nucleic Acid-based Drugs market. Readers of the report can become informed about current and future trends of the global Nucleic Acid-based Drugs market and how they will impact market growth during the forecast period.



By Company


Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
BioNTech
Moderna Therapeutics
CureVac
Alnylam Pharmaceuticals
Regulus Therapeutics
Miragen Therapeutics
Mina Therapeutics
NeXstar Pharmaceuticals
Segment by Type
ASO
mRNA
siRNA
miRNA
saRNA
Aptamer

Segment by Application


Genetic Disease
Cancer
Cardiovascular Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Nucleic Acid-based Drugs in global and regional level.
Chapter 3Detailed analysis of Nucleic Acid-based Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nucleic Acid-based Drugs revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nucleic Acid-based Drugs Market Size Growth Rate by Type: 2018 VS 2023 VS 2033
1.2.2 ASO
1.2.3 mRNA
1.2.4 siRNA
1.2.5 miRNA
1.2.6 saRNA
1.2.7 Aptamer
1.3 Market by Application
1.3.1 Global Nucleic Acid-based Drugs Market Growth Rate by Application: 2018 VS 2023 VS 2033
1.3.2 Genetic Disease
1.3.3 Cancer
1.3.4 Cardiovascular Diseases
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Nucleic Acid-based Drugs Market Size (2018-2033)
2.2 Nucleic Acid-based Drugs Market Size across Key Geographies Worldwide: 2018 VS 2023 VS 2033
2.3 Global Nucleic Acid-based Drugs Market Size by Region (2018-2023)
2.4 Global Nucleic Acid-based Drugs Market Size Forecast by Region (2024-2033)
2.5 Global Top 10 Nucleic Acid-based Drugs Countries Ranking by Market Size
3 Nucleic Acid-based Drugs Competitive by Company
3.1 Global Nucleic Acid-based Drugs Revenue by Players
3.1.1 Global Nucleic Acid-based Drugs Revenue by Players (2018-2023)
3.1.2 Global Nucleic Acid-based Drugs Market Share by Players (2018-2023)
3.2 Global Nucleic Acid-based Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Nucleic Acid-based Drugs Revenue
3.4 Global Nucleic Acid-based Drugs Market Concentration Ratio
3.4.1 Global Nucleic Acid-based Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid-based Drugs Revenue in 2023
3.5 Global Key Players of Nucleic Acid-based Drugs Head office and Area Served
3.6 Global Key Players of Nucleic Acid-based Drugs, Product and Application
3.7 Global Key Players of Nucleic Acid-based Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Nucleic Acid-based Drugs Breakdown Data by Type
4.1 Global Nucleic Acid-based Drugs Historic Revenue by Type (2018-2023)
4.2 Global Nucleic Acid-based Drugs Forecasted Revenue by Type (2024-2033)
5 Global Nucleic Acid-based Drugs Breakdown Data by Application
5.1 Global Nucleic Acid-based Drugs Historic Market Size by Application (2018-2023)
5.2 Global Nucleic Acid-based Drugs Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Nucleic Acid-based Drugs Revenue by Company (2021-2023)
6.2 North America Nucleic Acid-based Drugs Revenue by Type (2018-2033)
6.3 North America Nucleic Acid-based Drugs Revenue by Application (2018-2033)
6.4 North America Nucleic Acid-based Drugs Revenue by Country (2018-2033)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Nucleic Acid-based Drugs Revenue by Company (2021-2023)
7.2 Europe Nucleic Acid-based Drugs Revenue by Type (2018-2033)
7.3 Europe Nucleic Acid-based Drugs Revenue by Application (2018-2033)
7.4 Europe Nucleic Acid-based Drugs Revenue by Country (2018-2033)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Nucleic Acid-based Drugs Revenue by Company (2021-2023)
8.2 Asia Pacific Nucleic Acid-based Drugs Revenue by Type (2018-2033)
8.3 Asia Pacific Nucleic Acid-based Drugs Revenue by Application (2018-2033)
8.4 Asia Pacific Nucleic Acid-based Drugs Revenue by Region (2018-2033)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Nucleic Acid-based Drugs Revenue by Company (2021-2023)
9.2 Latin America Nucleic Acid-based Drugs Revenue by Type (2018-2033)
9.3 Latin America Nucleic Acid-based Drugs Revenue by Application (2018-2033)
9.4 Latin America Nucleic Acid-based Drugs Revenue by Country (2018-2033)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
9.4.4 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Nucleic Acid-based Drugs Revenue by Company (2021-2023)
10.2 Middle East and Africa Nucleic Acid-based Drugs Revenue by Type (2018-2033)
10.3 Middle East and Africa Nucleic Acid-based Drugs Revenue by Application (2018-2033)
10.4 Middle East and Africa Nucleic Acid-based Drugs Revenue by Country (2018-2033)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Company Details
11.1.2 Ionis Pharmaceuticals Business Overview
11.1.3 Ionis Pharmaceuticals Nucleic Acid-based Drugs Products and Services
11.1.4 Ionis Pharmaceuticals Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.1.5 Ionis Pharmaceuticals Nucleic Acid-based Drugs SWOT Analysis
11.1.6 Ionis Pharmaceuticals Recent Development
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Details
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Nucleic Acid-based Drugs Products and Services
11.2.4 Sarepta Therapeutics Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.2.5 Sarepta Therapeutics Nucleic Acid-based Drugs SWOT Analysis
11.2.6 Sarepta Therapeutics Recent Development
11.3 Nippon Shinyaku
11.3.1 Nippon Shinyaku Company Details
11.3.2 Nippon Shinyaku Business Overview
11.3.3 Nippon Shinyaku Nucleic Acid-based Drugs Products and Services
11.3.4 Nippon Shinyaku Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.3.5 Nippon Shinyaku Nucleic Acid-based Drugs SWOT Analysis
11.3.6 Nippon Shinyaku Recent Development
11.4 BioNTech
11.4.1 BioNTech Company Details
11.4.2 BioNTech Business Overview
11.4.3 BioNTech Nucleic Acid-based Drugs Products and Services
11.4.4 BioNTech Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.4.5 BioNTech Nucleic Acid-based Drugs SWOT Analysis
11.4.6 BioNTech Recent Development
11.5 Moderna Therapeutics
11.5.1 Moderna Therapeutics Company Details
11.5.2 Moderna Therapeutics Business Overview
11.5.3 Moderna Therapeutics Nucleic Acid-based Drugs Products and Services
11.5.4 Moderna Therapeutics Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.5.5 Moderna Therapeutics Nucleic Acid-based Drugs SWOT Analysis
11.5.6 Moderna Therapeutics Recent Development
11.6 CureVac
11.6.1 CureVac Company Details
11.6.2 CureVac Business Overview
11.6.3 CureVac Nucleic Acid-based Drugs Products and Services
11.6.4 CureVac Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.6.5 CureVac Nucleic Acid-based Drugs SWOT Analysis
11.6.6 CureVac Recent Development
11.7 Alnylam Pharmaceuticals
11.7.1 Alnylam Pharmaceuticals Company Details
11.7.2 Alnylam Pharmaceuticals Business Overview
11.7.3 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Products and Services
11.7.4 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.7.5 Alnylam Pharmaceuticals Nucleic Acid-based Drugs SWOT Analysis
11.7.6 Alnylam Pharmaceuticals Recent Development
11.8 Regulus Therapeutics
11.8.1 Regulus Therapeutics Company Details
11.8.2 Regulus Therapeutics Business Overview
11.8.3 Regulus Therapeutics Nucleic Acid-based Drugs Products and Services
11.8.4 Regulus Therapeutics Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.8.5 Regulus Therapeutics Nucleic Acid-based Drugs SWOT Analysis
11.8.6 Regulus Therapeutics Recent Development
11.9 Miragen Therapeutics
11.9.1 Miragen Therapeutics Company Details
11.9.2 Miragen Therapeutics Business Overview
11.9.3 Miragen Therapeutics Nucleic Acid-based Drugs Products and Services
11.9.4 Miragen Therapeutics Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.9.5 Miragen Therapeutics Nucleic Acid-based Drugs SWOT Analysis
11.9.6 Miragen Therapeutics Recent Development
11.10 Mina Therapeutics
11.10.1 Mina Therapeutics Company Details
11.10.2 Mina Therapeutics Business Overview
11.10.3 Mina Therapeutics Nucleic Acid-based Drugs Products and Services
11.10.4 Mina Therapeutics Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.10.5 Mina Therapeutics Nucleic Acid-based Drugs SWOT Analysis
11.10.6 Mina Therapeutics Recent Development
11.11 NeXstar Pharmaceuticals
11.11.1 NeXstar Pharmaceuticals Company Details
11.11.2 NeXstar Pharmaceuticals Business Overview
11.11.3 NeXstar Pharmaceuticals Nucleic Acid-based Drugs Products and Services
11.11.4 NeXstar Pharmaceuticals Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.11.5 NeXstar Pharmaceuticals Recent Development
12 Nucleic Acid-based Drugs Market Dynamics
12.1 Nucleic Acid-based Drugs Industry Trends
12.2 Nucleic Acid-based Drugs Market Drivers
12.3 Nucleic Acid-based Drugs Market Challenges
12.4 Nucleic Acid-based Drugs Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Nucleic Acid-based Drugs Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2023 VS 2033
Table 2. Key Players of ASO
Table 3. Key Players of mRNA
Table 4. Key Players of siRNA
Table 5. Key Players of miRNA
Table 6. Key Players of saRNA
Table 7. Key Players of Aptamer
Table 8. Global Nucleic Acid-based Drugs Market Size Growth Rate by Application (US$ Million), 2018 VS 2023 VS 2033
Table 9. Global Nucleic Acid-based Drugs Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2023 VS 2033
Table 10. Global Nucleic Acid-based Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 11. Global Nucleic Acid-based Drugs Revenue Forecast by Region (2024-2033) & (US$ Million)
Table 12. Global Nucleic Acid-based Drugs Market Size of Top 10 Countries, 2018 VS 2023 VS 2033, (US$ Million)
Table 13. Global Nucleic Acid-based Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 14. Global Nucleic Acid-based Drugs Market Share by Players (2018-2023)
Table 15. Global Top Nucleic Acid-based Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid-based Drugs as of 2023)
Table 16. Ranking of Global Top Nucleic Acid-based Drugs Companies by Revenue (US$ Million) in 2023
Table 17. Global 5 Largest Players Market Share by Nucleic Acid-based Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 18. Global Key Players of Nucleic Acid-based Drugs, Headquarters and Area Served
Table 19. Global Key Players of Nucleic Acid-based Drugs, Product and Application
Table 20. Global Key Players of Nucleic Acid-based Drugs, Date of Enter into This Industry
Table 21. Mergers & Acquisitions, Expansion Plans
Table 22. Global Nucleic Acid-based Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 23. Global Nucleic Acid-based Drugs Revenue Market Share by Type (2018-2023)
Table 24. Global Nucleic Acid-based Drugs Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 25. Global Nucleic Acid-based Drugs Revenue Market Share by Type (2024-2033)
Table 26. Global Nucleic Acid-based Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 27. Global Nucleic Acid-based Drugs Revenue Market Share by Application (2018-2023)
Table 28. Global Nucleic Acid-based Drugs Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 29. Global Nucleic Acid-based Drugs Revenue Market Share by Application (2024-2033)
Table 30. North America Nucleic Acid-based Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 31. North America Nucleic Acid-based Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 32. North America Nucleic Acid-based Drugs Revenue by Type (2024-2033) & (US$ Million)
Table 33. North America Nucleic Acid-based Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 34. North America Nucleic Acid-based Drugs Revenue by Application (2024-2033) & (US$ Million)
Table 35. North America Nucleic Acid-based Drugs Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 36. North America Nucleic Acid-based Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 37. North America Nucleic Acid-based Drugs Revenue by Country (2024-2033) & (US$ Million)
Table 38. Europe Nucleic Acid-based Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 39. Europe Nucleic Acid-based Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 40. Europe Nucleic Acid-based Drugs Revenue by Type (2024-2033) & (US$ Million)
Table 41. Europe Nucleic Acid-based Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 42. Europe Nucleic Acid-based Drugs Revenue by Application (2024-2033) & (US$ Million)
Table 43. Europe Nucleic Acid-based Drugs Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 44. Europe Nucleic Acid-based Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 45. Europe Nucleic Acid-based Drugs Revenue by Country (2024-2033) & (US$ Million)
Table 46. Asia Pacific Nucleic Acid-based Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 47. Asia Pacific Nucleic Acid-based Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 48. Asia Pacific Nucleic Acid-based Drugs Revenue by Type (2024-2033) & (US$ Million)
Table 49. Asia Pacific Nucleic Acid-based Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 50. Asia Pacific Nucleic Acid-based Drugs Revenue by Application (2024-2033) & (US$ Million)
Table 51. Asia-Pacific Nucleic Acid-based Drugs Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2023 VS 2033
Table 52. Asia Pacific Nucleic Acid-based Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 53. Asia Pacific Nucleic Acid-based Drugs Revenue by Region (2024-2033) & (US$ Million)
Table 54. Latin America Nucleic Acid-based Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 55. Latin America Nucleic Acid-based Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 56. Latin America Nucleic Acid-based Drugs Revenue by Type (2024-2033) & (US$ Million)
Table 57. Latin America Nucleic Acid-based Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 58. Latin America Nucleic Acid-based Drugs Revenue by Application (2024-2033) & (US$ Million)
Table 59. Latin America Nucleic Acid-based Drugs Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 60. Latin America Nucleic Acid-based Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 61. Latin America Nucleic Acid-based Drugs Revenue by Country (2024-2033) & (US$ Million)
Table 62. Middle East and Africa Nucleic Acid-based Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 63. Middle East and Africa Nucleic Acid-based Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 64. Middle East and Africa Nucleic Acid-based Drugs Revenue by Type (2024-2033) & (US$ Million)
Table 65. Middle East and Africa Nucleic Acid-based Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 66. Middle East and Africa Nucleic Acid-based Drugs Revenue by Application (2024-2033) & (US$ Million)
Table 67. Middle East and Africa Nucleic Acid-based Drugs Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 68. Middle East and Africa Nucleic Acid-based Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 69. Middle East and Africa Nucleic Acid-based Drugs Revenue by Country (2024-2033) & (US$ Million)
Table 70. Ionis Pharmaceuticals Company Details
Table 71. Ionis Pharmaceuticals Business Overview
Table 72. Ionis Pharmaceuticals Nucleic Acid-based Drugs Product and Services
Table 73. Ionis Pharmaceuticals Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023) & (US$ Million)
Table 74. Ionis Pharmaceuticals Nucleic Acid-based Drugs SWOT Analysis
Table 75. Ionis Pharmaceuticals Recent Development
Table 76. Sarepta Therapeutics Company Details
Table 77. Sarepta Therapeutics Business Overview
Table 78. Sarepta Therapeutics Nucleic Acid-based Drugs Product and Services
Table 79. Sarepta Therapeutics Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023) & (US$ Million)
Table 80. Sarepta Therapeutics Nucleic Acid-based Drugs SWOT Analysis
Table 81. Sarepta Therapeutics Recent Development
Table 82. Nippon Shinyaku Company Details
Table 83. Nippon Shinyaku Business Overview
Table 84. Nippon Shinyaku Nucleic Acid-based Drugs Product and Services
Table 85. Nippon Shinyaku Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023) & (US$ Million)
Table 86. Nippon Shinyaku Nucleic Acid-based Drugs SWOT Analysis
Table 87. Nippon Shinyaku Recent Development
Table 88. BioNTech Company Details
Table 89. BioNTech Business Overview
Table 90. BioNTech Nucleic Acid-based Drugs Product and Services
Table 91. BioNTech Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023) & (US$ Million)
Table 92. BioNTech Nucleic Acid-based Drugs SWOT Analysis
Table 93. BioNTech Recent Development
Table 94. Moderna Therapeutics Company Details
Table 95. Moderna Therapeutics Business Overview
Table 96. Moderna Therapeutics Nucleic Acid-based Drugs Product and Services
Table 97. Moderna Therapeutics Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023) & (US$ Million)
Table 98. Moderna Therapeutics Nucleic Acid-based Drugs SWOT Analysis
Table 99. Moderna Therapeutics Recent Development
Table 100. CureVac Company Details
Table 101. CureVac Business Overview
Table 102. CureVac Nucleic Acid-based Drugs Product and Services
Table 103. CureVac Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023) & (US$ Million)
Table 104. CureVac Nucleic Acid-based Drugs SWOT Analysis
Table 105. CureVac Recent Development
Table 106. Alnylam Pharmaceuticals Company Details
Table 107. Alnylam Pharmaceuticals Business Overview
Table 108. Alnylam Pharmaceuticals Nucleic Acid-based Drugs Product and Services
Table 109. Alnylam Pharmaceuticals Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023) & (US$ Million)
Table 110. Alnylam Pharmaceuticals Nucleic Acid-based Drugs SWOT Analysis
Table 111. Alnylam Pharmaceuticals Recent Development
Table 112. Regulus Therapeutics Company Details
Table 113. Regulus Therapeutics Business Overview
Table 114. Regulus Therapeutics Nucleic Acid-based Drugs Product and Services
Table 115. Regulus Therapeutics Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023) & (US$ Million)
Table 116. Regulus Therapeutics Nucleic Acid-based Drugs SWOT Analysis
Table 117. Regulus Therapeutics Recent Development
Table 118. Miragen Therapeutics Company Details
Table 119. Miragen Therapeutics Business Overview
Table 120. Miragen Therapeutics Nucleic Acid-based Drugs Product and Services
Table 121. Miragen Therapeutics Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023) & (US$ Million)
Table 122. Miragen Therapeutics Nucleic Acid-based Drugs SWOT Analysis
Table 123. Miragen Therapeutics Recent Development
Table 124. Mina Therapeutics Company Details
Table 125. Mina Therapeutics Business Overview
Table 126. Mina Therapeutics Nucleic Acid-based Drugs Product and Services
Table 127. Mina Therapeutics Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023) & (US$ Million)
Table 128. Mina Therapeutics Nucleic Acid-based Drugs SWOT Analysis
Table 129. Mina Therapeutics Recent Development
Table 130. NeXstar Pharmaceuticals Company Details
Table 131. NeXstar Pharmaceuticals Business Overview
Table 132. NeXstar Pharmaceuticals Nucleic Acid-based Drugs Product and Services
Table 133. NeXstar Pharmaceuticals Nucleic Acid-based Drugs Revenue in Nucleic Acid-based Drugs Business (2018-2023) & (US$ Million)
Table 134. NeXstar Pharmaceuticals Recent Development
Table 135. Nucleic Acid-based Drugs Market Trends
Table 136. Nucleic Acid-based Drugs Market Drivers
Table 137. Nucleic Acid-based Drugs Market Challenges
Table 138. Nucleic Acid-based Drugs Market Restraints
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Nucleic Acid-based Drugs Product Picture
Figure 2. Global Nucleic Acid-based Drugs Market Size by Type (US$ Million): 2018 VS 2023 VS 2033
Figure 3. Global Nucleic Acid-based Drugs Market Share by Type: 2023 VS 2033
Figure 4. ASO Features
Figure 5. mRNA Features
Figure 6. siRNA Features
Figure 7. miRNA Features
Figure 8. saRNA Features
Figure 9. Aptamer Features
Figure 10. Global Nucleic Acid-based Drugs Market Size by Application (US$ Million): 2018 VS 2023 VS 2033
Figure 11. Global Nucleic Acid-based Drugs Market Share by Application: 2023 VS 2033
Figure 12. Genetic Disease
Figure 13. Cancer
Figure 14. Cardiovascular Diseases
Figure 15. Other
Figure 16. Nucleic Acid-based Drugs Report Years Considered
Figure 17. Global Nucleic Acid-based Drugs Revenue, (US$ Million), 2018 VS 2023 VS 2033
Figure 18. Global Nucleic Acid-based Drugs Market Size 2018-2033 (US$ Million)
Figure 19. Global Nucleic Acid-based Drugs Market Size Market Share by Region: 2023 VS 2033
Figure 20. Global Nucleic Acid-based Drugs Revenue Market Share by Region in 2018 VS 2023
Figure 21. Global Nucleic Acid-based Drugs Revenue Market Share Forecast by Region (2024-2033)
Figure 22. Global Top 10 Nucleic Acid-based Drugs Countries Ranking by Market Size (US$ Million) in 2023
Figure 23. Global Nucleic Acid-based Drugs Market Size of Top 10 Countries, 2018 VS 2023 VS 2033, (US$ Million)
Figure 24. Global Nucleic Acid-based Drugs Market Share by Players in 2023
Figure 25. Global Top Nucleic Acid-based Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid-based Drugs as of 2023)
Figure 26. The Top 10 and 5 Players Market Share by Nucleic Acid-based Drugs Revenue in 2023
Figure 27. North America Nucleic Acid-based Drugs Revenue Market Share by Company in 2023
Figure 28. North America Nucleic Acid-based Drugs Revenue Market Share by Type (2018-2033)
Figure 29. North America Nucleic Acid-based Drugs Revenue Market Share by Application (2018-2033)
Figure 30. North America Nucleic Acid-based Drugs Revenue Share by Country (2018-2033)
Figure 31. United States Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 32. Canada Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 33. Europe Nucleic Acid-based Drugs Revenue Market Share by Company in 2023
Figure 34. Europe Nucleic Acid-based Drugs Revenue Market Share by Type (2018-2033)
Figure 35. Europe Nucleic Acid-based Drugs Revenue Market Share by Application (2018-2033)
Figure 36. Europe Nucleic Acid-based Drugs Revenue Share by Country (2018-2033)
Figure 37. Germany Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 38. France Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 39. U.K. Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 40. Italy Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 41. Russia Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 42. Asia Pacific Nucleic Acid-based Drugs Revenue Market Share by Company in 2023
Figure 43. Asia Pacific Nucleic Acid-based Drugs Revenue Market Share by Type (2018-2033)
Figure 44. Asia Pacific Nucleic Acid-based Drugs Revenue Market Share by Application (2018-2033)
Figure 45. Asia Pacific Nucleic Acid-based Drugs Revenue Share by Region (2018-2033)
Figure 46. China Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 47. Japan Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 48. South Korea Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 49. India Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 50. Australia Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 51. China Taiwan Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 52. Indonesia Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 53. Thailand Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 54. Malaysia Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 55. Latin America Nucleic Acid-based Drugs Revenue Market Share by Company in 2023
Figure 56. Latin America Nucleic Acid-based Drugs Revenue Market Share by Type (2018-2033)
Figure 57. Latin America Nucleic Acid-based Drugs Revenue Market Share by Application (2018-2033)
Figure 58. Latin America Nucleic Acid-based Drugs Revenue Share by Country (2018-2033)
Figure 59. Mexico Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 60. Brazil Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 61. Argentina Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 62. Colombia Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 63. Middle East and Africa Nucleic Acid-based Drugs Revenue Market Share by Company in 2023
Figure 64. Middle East and Africa Nucleic Acid-based Drugs Revenue Market Share by Type (2018-2033)
Figure 65. Middle East and Africa Nucleic Acid-based Drugs Revenue Market Share by Application (2018-2033)
Figure 66. Middle East and Africa Nucleic Acid-based Drugs Revenue Share by Country (2018-2033)
Figure 67. Turkey Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 68. Saudi Arabia Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 69. UAE Nucleic Acid-based Drugs Revenue (2018-2033) & (US$ Million)
Figure 70. Ionis Pharmaceuticals Revenue Growth Rate in Nucleic Acid-based Drugs Business (2018-2023)
Figure 71. Sarepta Therapeutics Revenue Growth Rate in Nucleic Acid-based Drugs Business (2018-2023)
Figure 72. Nippon Shinyaku Revenue Growth Rate in Nucleic Acid-based Drugs Business (2018-2023)
Figure 73. BioNTech Revenue Growth Rate in Nucleic Acid-based Drugs Business (2018-2023)
Figure 74. Moderna Therapeutics Revenue Growth Rate in Nucleic Acid-based Drugs Business (2018-2023)
Figure 75. CureVac Revenue Growth Rate in Nucleic Acid-based Drugs Business (2018-2023)
Figure 76. Alnylam Pharmaceuticals Revenue Growth Rate in Nucleic Acid-based Drugs Business (2018-2023)
Figure 77. Regulus Therapeutics Revenue Growth Rate in Nucleic Acid-based Drugs Business (2018-2023)
Figure 78. Miragen Therapeutics Revenue Growth Rate in Nucleic Acid-based Drugs Business (2018-2023)
Figure 79. Mina Therapeutics Revenue Growth Rate in Nucleic Acid-based Drugs Business (2018-2023)
Figure 80. NeXstar Pharmaceuticals Revenue Growth Rate in Nucleic Acid-based Drugs Business (2018-2023)
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries